8-K: Syndax Pharmaceuticals Reports Q1 2024 Financials and Advances Pipeline with Key Regulatory Milestones

Syndax Pharmaceuticals announced its first quarter 2024 financial results, highlighted by priority review designations for two key drug candidates and progress in clinical trials.

Summary

• Syndax Pharmaceuticals reported a net loss of $72.4 million, or $0.85 per share, for the first quarter of 2024, compared to a net loss of $41.1 million, or $0.59 per share, for the same period in 2023.
• Research and development expenses increased to $56.5 million in Q1 2024 from $34.1 million in Q1 2023, driven by increased clinical development and manufacturing costs.
• Selling, general, and administrative expenses rose to $23.0 million in Q1 2024 from $12.0 million in Q1 2023, due to increased employee-related expenses and commercialization activities.
• The company had $522.0 million in cash, cash equivalents, and short and long-term investments as of March 31, 2024.
• The FDA granted Priority Review for the NDA of revumenib with a PDUFA action date of September 26, 2024.
• The BLA for axatilimab was also granted Priority Review with a PDUFA action date of August 28, 2024.
• Enrollment is complete in the AUGMENT-101 mNPM1 cohort, with topline data expected in the fourth quarter of 2024.
• Syndax expects research and development expenses to be between $50 and $55 million for the second quarter of 2024 and total operating expenses to be between $80 and $85 million.
• For the full year 2024, the company anticipates research and development expenses of $240 to $260 million and total operating expenses of $355 to $375 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline with priority reviews and trial progress, the significant increase in net loss and operating expenses is concerning. The sentiment is cautiously optimistic, reflecting the potential for future success but acknowledging current financial challenges.

Positives

• Both revumenib and axatilimab have received Priority Review from the FDA, potentially leading to faster approvals.
• The completion of enrollment in the AUGMENT-101 mNPM1 cohort is a significant step towards a potential sNDA filing in the first half of 2025.
• The company has a strong cash position of $522 million, which is expected to fund operations through 2026.
• Syndax is expanding its clinical trials for revumenib into multiple combination therapies and indications.
• The appointment of a new Chief Commercial Officer indicates a focus on commercialization.

Negatives

• The company reported a significant increase in net loss for the first quarter of 2024, from $41.1 million to $72.4 million.
• Research and development expenses and selling, general, and administrative expenses have increased substantially compared to the same period last year.
• The company is still operating at a loss, with no revenue reported.

Risks

• The company's success is heavily dependent on the regulatory approval of revumenib and axatilimab.
• Clinical trial results may not be positive, which could delay or prevent regulatory approvals.
• Increased operating expenses could impact the company's financial stability.
• The company faces competition from other pharmaceutical companies developing cancer therapies.
• There are risks associated with the commercialization of new drugs, including market acceptance and pricing.

Future Outlook

The company anticipates potential near-term approvals for revumenib and axatilimab in the third quarter of 2024 and pivotal data from the mNPM1 cohort of the AUGMENT-101 trial in the fourth quarter of 2024. Syndax believes it has sufficient cash to fund operations through 2026.

Management Comments

• With the potential near-term approvals of revumenib and axatilimab in the third quarter as well as pivotal data from the mNPM1 cohort of the AUGMENT-101 trial in the fourth quarter, the Company is on track to have a historic year punctuated by major value-creating milestones, said Michael A. Metzger, Chief Executive Officer.
• Syndax is unparalleled as a SMID cap oncology company with the potential launch of two firstand best-in-class agents into multi-billion-dollar markets with the opportunity for expansion beyond their initial indications.
• We remain keenly focused on laying the foundation and building an experienced team of experts to ensure our successful transition into a commercial organization.

Industry Context

Syndax is operating in the competitive oncology biopharmaceutical space, focusing on developing targeted therapies for specific cancer subtypes. The company's progress with revumenib and axatilimab aligns with the industry trend towards precision medicine and personalized treatments. The priority review designations from the FDA highlight the potential significance of these therapies in addressing unmet medical needs.

Comparison to Industry Standards

• Syndax's focus on targeted therapies like revumenib and axatilimab aligns with the industry trend towards precision medicine, similar to companies like Blueprint Medicines and Loxo Oncology (now part of Eli Lilly).
• The priority review designations for both drugs are a positive sign, indicating the FDA's recognition of their potential to address unmet medical needs, similar to other companies that have received priority review for their oncology drugs.
• The company's cash runway through 2026 is a positive indicator of financial stability, comparable to other clinical-stage biopharma companies with similar funding levels.
• The increase in R&D and SG&A expenses is typical for a company advancing multiple clinical programs and preparing for commercialization, similar to other companies in the sector.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the increased net loss, but also by the potential for future revenue from drug approvals.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to advance clinical trials for revumenib and axatilimab.
• Syndax will prepare for potential commercial launches of revumenib and axatilimab.
• Topline data from the AUGMENT-101 mNPM1 cohort is expected in the fourth quarter of 2024.
• The company plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.
• The company expects to provide an update on the Phase 1 proof-of-concept clinical trial of revumenib in patients with unresectable metastatic microsatellite stable colorectal cancer in the second quarter of 2024.

Key Dates

Keywords

revumenib, axatilimab, acute leukemia, chronic GVHD, KMT2Ar, mNPM1, FDA, Priority Review, PDUFA, clinical trials, biopharmaceutical, oncology